Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease.
Hepatitis C virus (HCV) is the most common cause of end-stage liver disease in transplant recipients. Progression of recurrent HCV infection is accelerated. Cyclosporine is not only an immunosuppressive drug, but also an anti-HCV drug. We reported here the beneficial effect of combined interferon and cyclosporine treatment for chronic hepatitis C. We recommend this protocol for established HCV-related graft disease.
Inoue
K
K
Showa University Fujigaoka Hospital, Yokohama, Japan. Kazuaki-inoue@showa-university-fujigaoka.gr.jp
Yoshiba
M
M
D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006526:Hepatitis C / Q000517:prevention & control*; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use*; D017093:Liver Failure / Q000601:surgery / Q000821:virology*; D016031:Liver Transplantation / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D012008:Recurrence; D012449:Safety; D019562:Viral Load
D000998:Antiviral Agents; D012367:RNA, Viral; D016899:Interferon-beta; D016572:Cyclosporine